Gut Bacteria Produce Compound That Fights Colorectal Cancer Through AKT1 Pathway
Researchers discover N-acetylmuramic acid from gut microbes inhibits colorectal cancer by blocking AKT1 signaling, offering new prevention insights.
Summary
Scientists identified N-acetylmuramic acid (NAM), a compound produced by gut bacteria, that significantly protects against colorectal cancer. Analysis of over 1,100 patients revealed NAM levels decrease as cancer progresses. Laboratory studies showed NAM directly binds to and inhibits AKT1, a key protein driving cancer growth. The compound successfully reduced tumor formation in multiple mouse models and slowed growth of patient-derived cancer organoids. This discovery suggests gut microbe health may be crucial for cancer prevention.
Detailed Summary
This groundbreaking research reveals how gut bacteria may naturally protect against colorectal cancer through a previously unknown mechanism. The study matters because colorectal cancer remains a leading cause of cancer deaths, and understanding protective factors could revolutionize prevention strategies.
Researchers analyzed gut microbiome data from 1,121 patients across seven independent studies, discovering that genes responsible for producing peptidoglycan fragments were significantly reduced in colorectal cancer patients. Using advanced mass spectrometry, they identified N-acetylmuramic acid (NAM) as a key protective compound that becomes depleted as cancer progresses.
Laboratory experiments demonstrated NAM's remarkable anti-cancer properties. The compound inhibited tumor formation in multiple mouse models and reduced growth of patient-derived cancer organoids in a dose-dependent manner. Mechanistically, NAM works by directly binding to AKT1, a crucial protein that promotes cancer cell survival and growth, preventing its activation.
These findings suggest that maintaining healthy gut bacteria capable of producing NAM could be a natural defense against colorectal cancer. The research opens new avenues for both prevention and treatment, potentially through probiotic interventions or NAM supplementation. However, human clinical trials are needed to confirm these protective effects and establish optimal dosing strategies for cancer prevention.
Key Findings
- NAM levels significantly decrease in colorectal cancer patients as tumors progress
- NAM directly binds to AKT1 protein, blocking cancer-promoting phosphorylation
- Treatment with NAM reduced tumor formation in multiple mouse cancer models
- Patient-derived cancer organoids showed dose-dependent growth inhibition with NAM
- Gut bacteria genes for peptidoglycan production are depleted in cancer patients
Methodology
Study combined metagenomic analysis of 1,121 patients across seven cohorts with targeted mass spectrometry for metabolite quantification. Researchers used multiple mouse cancer models, patient-derived organoids, and molecular binding assays to evaluate NAM's anti-cancer mechanisms.
Study Limitations
Study is based on preclinical models and patient samples; human clinical trials are needed to confirm protective effects. Optimal dosing, delivery methods, and long-term safety of NAM supplementation remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.